Navigation Links
Mayo Clinic: Raoul Tibes, M.D., Ph.D., to receive Career Development Award
Date:6/3/2011

CHICAGO -- Rauol Tibes, M.D., Ph.D., the associate director of the Acute and Chronic Leukemias Program at Mayo Clinic in Arizona, will receive a Career Development Award from the Conquer Cancer Foundation of the American Society of Clinical Oncology (formerly known as the ASCO Cancer Foundation) at the annual ASCO meeting this weekend in Chicago.

VIDEO ALERT: Additional audio and video resources are available at the Mayo Clinic News Blog.

Dr. Tibes is one of only eight researchers in the United States selected to receive the Conquer Cancer Foundation of ASCO Career Development Award this year. The award, a three year grant totaling $200,000, will help fund the next phase of Mayo Clinic's translational research in acute myeloid leukemia (AML) led by Dr. Tibes and his team of colleagues.

The Career Development Awards are presented to physicians who are within their first to third year of full-time, primary faculty appointment in a clinical department at an academic medical institution.

"I am very happy and proud," said Dr. Tibes, upon learning that his research effort from his laboratory, designed to advance new therapies for patients with acute leukemias, was recognized with this honor.

The crux of this translational research focuses on how to make the drug Cytarabine (one of the most actively used drugs administered to leukemia patients), more potent and effective, particularly for leukemia patients who have failed prior therapies and whose leukemia has relapsed.

Dr. Tibes said this kind of translational research project was greatly accelerated when he and his team began adapting RNA interference (RNAi) to leukemia research.

"We performed a large scale RNAi screening knocking down (or inhibiting) 572 kinases (genes that drive growth)," explained Dr. Tibes. "As a result, when the WEE1 kinase was inhibited, a more potent effect of Cytarabine was produced."

"This technology allowed us to select the gene, out of hundreds to thousands of genes, that most strongly enhances the activity of Cytarabine. This is a tremendous selection to pick the "winner" gene that can then be targeted with new drugs together with Cytarabine," said Dr. Tibes, who, along with his laboratory team, is performing similar RNAi screens for other commonly used cancer drugs with the goal of accelerating the design of new therapies for Mayo Clinic.

Dr. Tibes said the proposed next step is to take the positive findings of the Cytarabine combination with the WEE1 kinase inhibitor he has seen in the laboratory setting and translate it to a clinical trial to see if it is a more effective therapy for patients with advanced, acute and chronic leukemias.

"One of our goals at Mayo Clinic is to improve patient care through translational research," said Keith Stewart, M.B.Ch.B., dean of research at Mayo Clinic in Arizona. "It is our hope this research may offer leukemia patients a treatment alternative when standard therapies fail," Dr. Stewart added.

"One of the big challenges, especially for acute leukemias, is that therapies haven't changed in decades. The treatment of acute leukemias, specifically AML has lagged behind. We aim to find new therapeutic combinations for patients with this research," said Ruben Mesa, M.D., chair, Division of Hematology and Medical Oncology at Mayo Clinic in Arizona.


'/>"/>

Contact: Julie Janovsky-Mason
newsbureau@mayo.edu
480-301-4222
Mayo Clinic
Source:Eurekalert

Related medicine news :

1. Atlanta School of Massage Celebrates 30th Anniversary with a New Green Design and New Name for its Teaching Clinic: SensAbility
2. AMA Honors Vice Admiral John Mateczun, M.D., With Top Government Service Award
3. Nationally Known Interventional Neuroradiologist John Pile-Spellman, M.D., Joins Neurological Surgery, P.C.
4. University of Utah afib specialist, Marcos Daccarett, M.D., wins Young Investigator Award
5. Joan Miller, M.D., receives 2010 Leadership Award for the Advancement of Women Faculty
6. Gino Tutera, M.D., F.A.C.O.G. Brings SottoPelle Therapy to Middle Tennessee, Opens Practice in Nashville Medical District
7. Renowned Psychiatrist, Lyubov Y Gorelik, M.D., is selected to represent New York in The Leading Physicians of the World
8. Anthony S. Fauci, M.D., on results from the CAPRISA 004 microbicide study
9. O. Marion Burton, M.D., F.A.A.P., addresses American Academy of Pediatrics in new term as president
10. Douglas A. Jabs, M.D., honored with Jackson Memorial Lecture by the American Academy of Ophthalmology
11. Donald M. Lloyd-Jones, M.D., recipient of the American Heart Associations 2010 Chairmans Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... ... March 30, 2017 , ... ... educational offerings of corporate finance programs to address the increasingly complex educational needs ... executives increase their knowledge of sophisticated corporate finance and will increase their ability ...
(Date:3/30/2017)... , ... March 30, 2017 , ... ... submitted a letter to President Trump expressing their support for an independent Vaccine ... two Ph.D. scientists and one medical journalist, will hold a press conference at ...
(Date:3/29/2017)... (PRWEB) , ... March 29, 2017 , ... Full Contact ... founder of Pet Protect Law that assists dog owners in creating legally-enforceable ... new owners in taking the natural next step to protect their new companion. Says ...
(Date:3/29/2017)... ... March 30, 2017 , ... Sports Brand EXOUS Bodygear announced today ... normally at $29.97; for the remaining days of March, the price will be only ... a special price of just $10 (regular retail price $19.97). , The special promotional ...
(Date:3/29/2017)... ... March 29, 2017 , ... Patients interested ... Carnegie, OK, from Dr. Jamie Cameron, with or without a referral. The FASTBRACES ... orthodontic treatment. Depending on each patient’s case, treatment with the FASTBRACES system could ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... 2017  Experts in the field in alcohol ... Soberlink Systems  as a model for recovery through ... early 2017, concluded that remote blood alcohol monitoring ... recovery." The findings of the expert ... detail a range of variables that are commonplace ...
(Date:3/29/2017)... March 29, 2017  Glenmark Pharmaceuticals, a global ... 301, an investigational fixed-dose combination of mometasone furoate ... twice-daily as a nasal spray being studied for ... are from a recently completed Phase 3 trial ... combination therapy versus mometasone, olopatadine or placebo. ...
(Date:3/29/2017)... 29, 2017 Research and Markets has announced ... report to their offering. ... The global lifestyle drugs market to grow at a ... report, Global Lifestyle Drugs Market 2017-2021, has been prepared based on ... covers the market landscape and its growth prospects over the coming ...
Breaking Medicine Technology: